Dosage research on GHK-Cu

Preclinical research dose ranges

In published preclinical research on GHK-Cu, dose conventions differ sharply by model system. The dermal-regeneration literature (dermal fibroblast and keratinocyte cell culture) has most commonly reported nanomolar to low-micromolar concentrations of GHK-Cu in the in-vitro culture medium, with the keratinocyte integrin and p63 expression work concentrating at the 1 to 10 nanomolar range and the dermal fibroblast matrix-remodeling work concentrating in the 0.1 to 1 micromolar range.

In-vivo dermal application studies have most commonly reported topical concentrations between 0.01 and 0.3 percent applied to the skin surface over daily-dosing protocols spanning weeks. The hair-follicle research literature has used both topical concentrations in the same range and intradermal injection at micromolar concentrations in the injected solution. Wound-healing animal studies have most commonly reported topical concentrations between 0.05 and 0.5 percent applied to the wound surface daily across the observation window.

Subcutaneous administration appears in a smaller subset of the in-vivo literature, primarily in oxidative-stress and gene-expression work where systemic exposure is the experimental requirement. Subcutaneous dose levels in rodent studies have most commonly fallen in the 0.5 to 5 milligram per kilogram range. The injectable-research-reagent supply format (a lyophilised vial reconstituted in bacteriostatic water) is most relevant to the subcutaneous and intradermal injection literature; topical formulation is typically not derived directly from the lyophilised research-vial form.

Dose-response considerations from the published literature

The published GHK-Cu literature has reported dose-response characteristics that vary by model system. In dermal fibroblast culture, matrix-remodeling endpoints have shown dose-response effects across the 0.1 to 1 micromolar range with plateau effects above that. In keratinocyte culture, integrin and p63 expression effects have shown dose-response across the 1 to 10 nanomolar range with the Kang and colleagues 2009 work reporting the canonical dose-response curve for that endpoint.

In-vivo topical-application dose-response work has reported maximum dermal regeneration effects at the 0.05 to 0.3 percent topical concentration range with no additional benefit at higher concentrations. Investigators publishing in the field have noted that the copper-bound form is integral to the active species and that uncomplexed GHK does not reproduce the dose-response characteristics of the GHK-Cu complex (a distinction relevant to interpreting in-vitro and in-vivo studies where the source material’s complexation state is sometimes not fully specified).

No Phase 1 or Phase 2 dose-ranging trial of GHK-Cu specifically has appeared in the indexed clinical-trial literature for systemic administration. Cosmetic-science clinical trials of topical GHK-Cu formulations exist in the dermatology literature and have used topical concentrations in the 0.01 to 0.1 percent range over multi-week observation windows, but those are formulated-product trials rather than research-reagent dose-ranging trials. The GHK-Cu research community continues to rely on the in-vitro and in-vivo rodent literature for dose-design inference.

Reconstitution math and per-vial dose calculation

A 50 mg lyophilised GHK-Cu vial reconstituted with 5 mL of bacteriostatic water yields a stock concentration of 10 mg per mL, which is the most common stock concentration in published in-vivo and intradermal protocols using GHK-Cu from research-grade lyophilised vials. From this stock, a research aliquot of 0.1 mL contains 1 milligram of GHK-Cu; an aliquot of 0.05 mL contains 500 micrograms. Researchers working with the in-vitro nanomolar to micromolar concentration ranges reported in cell-culture studies further dilute the stock by several orders of magnitude into the working culture medium. The reconstituted aliquot is refrigerated at 2 to 8 degrees Celsius, protected from light, and additionally protected from oxidising conditions to preserve the copper-bound form; standard peptide-handling practice in the published literature reports stability of the reconstituted material across the experimental observation window when these storage conditions are maintained.

Research-protocol design considerations

Protocol-design choices in the published GHK-Cu literature reflect several recurring considerations. Dose selection anchors at the concentration range that matches the model: nanomolar to low-micromolar for in-vitro cell culture; topical percent-concentration for in-vivo dermal and hair-follicle work; sub-milligram-per-kilogram to low-milligram-per-kilogram for in-vivo subcutaneous and gene-expression work. Investigators designing a new study begin at the anchor that matches their model and add comparator arms above and below.

Route of administration in the published in-vivo work is chosen to match the endpoint. Topical application is the dominant route for dermal, hair-follicle, and wound-healing endpoints. Intradermal injection appears in studies examining localised tissue endpoints. Subcutaneous administration appears in the oxidative-stress and gene-expression literature where systemic exposure is the requirement. Intravenous administration is uncommon in the published GHK-Cu literature.

Copper-bound complexation state is a protocol-design consideration that does not appear in most other peptide research. Investigators have noted that the published mechanistic literature consistently describes the Cu-bound form as the active species, and that working with uncomplexed GHK as the starting material produces a different chemistry profile. Research-grade GHK-Cu vials in the Cu-bound lyophilised form preserve the complexation state across reconstitution, with the storage caveat that the reconstituted material should be protected from strongly oxidising conditions to maintain the active species.

References

1. Hureau C et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Journal of Inorganic Biochemistry, 2001. [PMID 11325542]
2. Beretta E et al. Glycyl-histidyl-lysine (GHK) is a quencher of alpha,beta-4-hydroxy-trans-2-nonenal: a comparative study with other peptides. Free Radical Research, 2007. [PMID 17672515]
3. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. [PMID 18644225]
4. Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research, 2009. [PMID 19319546]
5. Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxidative Medicine and Cellular Longevity, 2012. [PMID 22666519]
6. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015. [PMID 26236730]
7. Pickart L et al. The effect of the human peptide GHK on gene expression relevant to nervous system function. Brain Sciences, 2017. [PMID 28212278]
8. Pickart L et al. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. [PMID 29986520]